AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of health benefits
Number of subjects: 490
Study 15836935 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic Scoliosis patients
Number of subjects: 40
Study 15836935 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adolescent females)
Number of subjects: 40
Study 12028852 — intervention group
Group type: EXPERIMENTAL
Intervention: BACCOFF + DIPSTOP
Number of subjects: 22
Study 12028852 — intervention group
Group type: COMPARATOR
Intervention: BACCOFF + placebo control
Number of subjects: 22
Study 12028852 — intervention group
Group type: COMPARATOR
Intervention: DIPSTOP
Number of subjects: 22
Study 12028852 — intervention group
Group type: COMPARATOR
Intervention: placebo control only
Number of subjects: 22
Study 10488712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in hepatocellular carcinoma
Number of subjects: 29
Study 10488712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in adenomatous hyperplasia
Number of subjects: 29
Study 10488712 — intervention group
Group type: COMPARATOR
Intervention: Telomerase activity in non-tumorous liver tissue
Number of subjects: 29
Study 10488712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in small tumors (≤2 cm)
Number of subjects: 29
Study 10488712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in larger tumors (>2 cm)
Number of subjects: 29
Study 8706450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (polymerized bovine hemoglobin)
Number of subjects: 41
Study 8706450 — intervention group
Group type: COMPARATOR
Intervention: Control infusion of lactated Ringer's solution
Number of subjects: 41
Study 1860763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic high-osmolar contrast medium (diatrizoate)
Number of subjects: 100
Study 1860763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic low-osmolar contrast medium (iopamidol)
Number of subjects: 100
Study 1860763 — intervention group
Group type: EXPERIMENTAL
Intervention: Single plasma sample at 3 hours
Number of subjects: 100
Study 1860763 — intervention group
Group type: EXPERIMENTAL
Intervention: Two plasma samples
Number of subjects: 100
Study 6360817 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and cis-platinum
Number of subjects: 19
Study 6360817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin synthesis inhibitors (acetylsalicyclic acid or indomethacin) during cytostatic infusion
Number of subjects: 19
Study 6360817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 6360817 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual ovarian cancer
Number of subjects: 19
Study 30557443 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone
Number of subjects: 570
Study 30557443 — intervention group
Group type: COMPARATOR
Intervention: Extended-release naltrexone
Number of subjects: 570
Study 29985202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin, maximally tolerated angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker, and low-dose aspirin
Number of subjects: 0
Study 29985202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative empiric treatment or further diagnostic evaluation of the coronary microvasculature
Number of subjects: 0
Study 29985202 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional antianginal and antiatherosclerotic medications
Number of subjects: 0
Study 26725287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization within three months of index hospitalization
Number of subjects: 373
Study 26725287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 373
Study 26905703 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg
Number of subjects: 60
Study 26905703 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2 mg/kg
Number of subjects: 60
Study 21726907 — intervention group
Group type: EXPERIMENTAL
Intervention: Taipei Osteoarthritis Program (TOAP) - 4 weeks duration
Number of subjects: 205
Study 21726907 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 205
Study 19495958 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m(2) weekly
Number of subjects: 300
Study 19495958 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2) weekly
Number of subjects: 300
Study 19495958 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 300 mg/m(2) q3w
Number of subjects: 300
Study 19495958 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 100 mg/m(2) q3w
Number of subjects: 300
Study 16533865 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 2
Study 16533865 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (21 days treatment)
Number of subjects: 2
Study 16536960 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 72
Study 16536960 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 72
Study 16536960 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 72
Study 16536960 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participants
Number of subjects: 72
Study 14551680 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin for 14 days (group 1)
Number of subjects: 92
Study 14551680 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin for at least 14 days (group 2)
Number of subjects: 92
Study 10896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (900 mg)
Number of subjects: 60
Study 10896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 60
Study 10896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 60
Study 10896014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10896014 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 8938165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous acetic acid injection (15%, 20%, 30%, 40%, and 50% concentration)
Number of subjects: 28
Study 8938165 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection alone
Number of subjects: 28
Study 8938165 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection after transcatheter arterial embolization
Number of subjects: 28
Study 1410729 — intervention group
Group type: EXPERIMENTAL
Intervention: ASL 900 mg and meperidine 100 mg/8 h (Group C)
Number of subjects: 160
Study 1410729 — intervention group
Group type: EXPERIMENTAL
Intervention: ASL 900 mg and 1.800 mg/8 h together with meperidine 100 mg/8 h (Group D)
Number of subjects: 160
Study 1410729 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 50 mg and 100 mg/8 h (Group G)
Number of subjects: 160
Study 1410729 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 50 mg and 100 mg/8 h together with ASL 1.800 mg/8 h (Group H)
Number of subjects: 160
Study 1410729 — intervention group
Group type: COMPARATOR
Intervention: ASL 900 mg and 1.800 mg/8 h (Group A)
Number of subjects: 160
Study 1410729 — intervention group
Group type: COMPARATOR
Intervention: ASL 900 mg and 3.600 mg/8 h (Group B)
Number of subjects: 160
Study 1410729 — intervention group
Group type: COMPARATOR
Intervention: meperidine 50 mg and ASL 1.800 mg/8 h (Group E)
Number of subjects: 160
Study 1410729 — intervention group
Group type: COMPARATOR
Intervention: meperidine 50 mg and ASL 3.600 mg/8 h (Group F)
Number of subjects: 160
Study 6731324 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 490
Study 6731324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 31725428 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC/DTG
Number of subjects: 48
Study 28967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg twice daily for 7 days with CsA 50 mg
Number of subjects: 0
Study 28967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg twice daily for 11 days with TAC 5 mg
Number of subjects: 0
Study 28967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice daily for 14 days with CsA 50 mg
Number of subjects: 0
Study 28967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice daily for 14 days with CsA 200 mg
Number of subjects: 0
Study 28967706 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC coadministered with letermovir
Number of subjects: 0
Study 26484738 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radiosurgery (single-session, frameless, image-guided); tumor dose of 18-22 Gy (mean 20.3 Gy) prescribed to the 70% isodose line.
Number of subjects: 217
Study 25294382 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor physical activity (quartiles)
Number of subjects: 419
Study 25294382 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin D intake (quartiles)
Number of subjects: 419
Study 22248392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg daily plus standard care
Number of subjects: 75
Study 22248392 — intervention group
Group type: COMPARATOR
Intervention: Standard care (surgical debridement + culture-specific antibiotics + offloading + glycaemic control)
Number of subjects: 75
Study 22248392 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 20404622 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 50
Study 20404622 — intervention group
Group type: COMPARATOR
Intervention: No BIS monitoring (Control)
Number of subjects: 50
Study 18623974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni‐Ti rotary files
Number of subjects: 26
Study 18623974 — intervention group
Group type: COMPARATOR
Intervention: Manual stainless steel files
Number of subjects: 26
Study 16425386 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules
Number of subjects: 43
Study 16425386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11877662 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 140
Study 10513830 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind)
Number of subjects: 383
Study 10513830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 10513830 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind) in ISH subgroup
Number of subjects: 383
Study 10513830 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Per/Ind and placebo)
Number of subjects: 383
Study 8924392 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive education program
Number of subjects: 0
Study 8924392 — intervention group
Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 0
Study 1708528 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 289
Study 1708528 — intervention group
Group type: COMPARATOR
Intervention: dextran 70
Number of subjects: 289
Study 6181329 — intervention group
Group type: EXPERIMENTAL
Intervention: Endralazine (10-20 mg t.i.d.)
Number of subjects: 23
Study 6181329 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (25-50 mg t.i.d.)
Number of subjects: 23
Study 31390073 — intervention group
Group type: EXPERIMENTAL
Intervention: Short video tutorial advising how to help children cope with fearful situations
Number of subjects: 72
Study 31390073 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 72
Study 30657853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg Q3W
Number of subjects: 1033
Study 30657853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (archival samples)
Number of subjects: 1033
Study 30657853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (newly collected samples)
Number of subjects: 1033
Study 30657853 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1033
Study 29289446 — intervention group
Group type: COMPARATOR
Intervention: Cluster-hole acetabular components
Number of subjects: 100
Study 29289446 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid-backed acetabular components
Number of subjects: 100
Study 29289446 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw group (patients requiring screws for stability)
Number of subjects: 100
Study 26453968 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir 150mg once daily without ribavirin
Number of subjects: 168
Study 26453968 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir 150mg once daily with ribavirin
Number of subjects: 168
Study 26453968 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir with ribavirin for 24 weeks
Number of subjects: 168
Study 26453968 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir 30mg plus simeprevir with ribavirin
Number of subjects: 168
Study 26453968 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir 30mg plus simeprevir without ribavirin
Number of subjects: 168
Study 23544953 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting intervention based on the Triple P-Positive Parenting Programme
Number of subjects: 39
Study 23544953 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 39
Study 22018509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g DHA-rich fish oil
Number of subjects: 22
Study 22018509 — intervention group
Group type: COMPARATOR
Intervention: 1 g EPA-rich fish oil
Number of subjects: 22
Study 22018509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g olive oil)
Number of subjects: 22
Study 19597169 — intervention group
Group type: EXPERIMENTAL
Intervention: HIOH delivered in the home
Number of subjects: 415
Study 19597169 — intervention group
Group type: EXPERIMENTAL
Intervention: HIOH delivered by telephone
Number of subjects: 415
Study 19597169 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 17052816 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 46
Study 16508679 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation radiotherapy (CF) (5 fractions per week)
Number of subjects: 60
Study 16508679 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (AF) (6 fractions per week)
Number of subjects: 60
Study 16508679 — intervention group
Group type: EXPERIMENTAL
Intervention: AF plus Mitomycin C (MMC)
Number of subjects: 60
Study 11986501 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically validated skills training program for self-management
Number of subjects: 0
Study 11986501 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 9818496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VACS) extract, 2 x 30 drops/day for 3 menstrual cycles
Number of subjects: 97
Study 9818496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7862879 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (178 mg)
Number of subjects: 7
Study 7862879 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (560 mg)
Number of subjects: 7
Study 7862879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2492454 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA (1.5 mg/kg/4 hr) and heparin (10,000 units bolus)
Number of subjects: 134
Study 2492454 — intervention group
Group type: COMPARATOR
Intervention: t‐PA (1.5 mg/kg/4 hr) only
Number of subjects: 134
Study 2492454 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and heparin
Number of subjects: 134
Study 2492454 — intervention group
Group type: COMPARATOR
Intervention: t‐PA only
Number of subjects: 134
Study 1095107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 120
Study 1095107 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin indanyl ester
Number of subjects: 120
Study 1095107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuratel
Number of subjects: 120
Study 1095107 — intervention group
Group type: COMPARATOR
Intervention: Penicillin drugs (control group)
Number of subjects: 120
Study 31670790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (DP)
Number of subjects: 28
Study 31670790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (DPTN)
Number of subjects: 28
Study 30623408 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 0·1%
Number of subjects: 194
Study 30623408 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 0·3%
Number of subjects: 194
Study 30623408 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 1·0%
Number of subjects: 194
Study 30623408 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 194
Study 27464957 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM) with oximetry, temperature, pulse, electrocardiogram, blood pressure, spirometry, and weight monitoring, along with telephone support and home visits
Number of subjects: 42
Study 27464957 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only identical telephone support and home visits
Number of subjects: 42
Study 26415793 — intervention group
Group type: EXPERIMENTAL
Intervention: 6, 8, 10, 12, or 14 mg intrathecal hyperbaric ropivacaine with 5 μg sufentanil
Number of subjects: 75
Study 22535635 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dialysis therapy with constant ultrafiltration (UF) rate, cool dialysate and high sodium conductivity (Treatment A)
Number of subjects: 74
Study 22535635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis regimens with adjunctive interventions including blood volume (BV) control (Treatment B)
Number of subjects: 74
Study 22535635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis regimens with the combination of BV and active blood temperature control (Treatment C)
Number of subjects: 74
Study 22535635 — intervention group
Group type: COMPARATOR
Intervention: All treatments (A, B, C)
Number of subjects: 74
Study 21762628 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus oxaliplatin (GO)
Number of subjects: 66
Study 21762628 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 66
Study 19147343 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preoperative radiotherapy (PRT)
Number of subjects: 0
Study 19147343 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy (PRT)
Number of subjects: 0
Study 19147343 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with or without preoperative radiotherapy (PRT)
Number of subjects: 0
Study 16749917 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera (AV)
Number of subjects: 58
Study 16749917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15072869 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg/day
Number of subjects: 120
Study 15072869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine 2 g/day plus acetyl‐L‐carnitine 2 g/day
Number of subjects: 120
Study 15072869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 120
Study 15230299 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10511349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 127
Study 10511349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 127
Study 10511349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 10511349 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 127
Study 8524560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring by community optometrists
Number of subjects: 8
Study 2107926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (mean of 114 mg daily) and lecithin (1200 mg daily)
Number of subjects: 67
Study 2107926 — intervention group
Group type: COMPARATOR
Intervention: Placebo and lecithin (1200 mg daily)
Number of subjects: 67
Study 395519 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 395519 — intervention group
Group type: COMPARATOR
Intervention: Mestranol with norethynodrel (Enavid, Searle)
Number of subjects: 0
Study 30235949 — intervention group
Group type: EXPERIMENTAL
Intervention: music-with-movement intervention
Number of subjects: 165
Study 30235949 — intervention group
Group type: COMPARATOR
Intervention: music listening
Number of subjects: 165
Study 30235949 — intervention group
Group type: COMPARATOR
Intervention: social activities
Number of subjects: 165
Study 30933384 — intervention group
Group type: EXPERIMENTAL
Intervention: 980‐nm diode laser (DL) irradiation in combination with mechanical therapy (setting 980 nm, 2.5 W, 10 kHz, pw, 30 s)
Number of subjects: 220
Study 30933384 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement using curettes and ultrasonic devices
Number of subjects: 220
Study 30933384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapeutic modalities
Number of subjects: 220
Study 29072018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using the Midnight-noon Ebb-flow method combined with syndrome differentiation for 3 months
Number of subjects: 136
Study 29072018 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment for language rehabilitation
Number of subjects: 136
Study 29072018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 136
Study 25808378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradually increasing retraction force
Number of subjects: 12
Study 25808378 — intervention group
Group type: COMPARATOR
Intervention: Relatively constant continuous retraction force
Number of subjects: 12
Study 24684757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 450